Canada authorizes Moderna’s flu and combo flu-COVID vaccines
Canada granted approval to Moderna's mRNA vaccines for individuals over 50 years old, including mFLUSIVA, an influenza vaccine, and mCOFLU, a flu-COVID combination vaccine. This makes Canada the first country to authorize both vaccines. mFLUSIVA, the first mRNA-based seasonal influenza vaccine in Canada, received FDA approval in August 2026 and EU authorization in April 2026. mCOFLU, the first flu-COVID combination vaccine in Canada, received authorization after a Phase 3 trial involving around 8,000 adults, which demonstrated non-inferiority of immune responses compared to licensed comparator vaccines.
Common side effects for both vaccines included mild to moderate reactions such as injection-site pain, fatigue, headache, muscle pain, joint pain, chills, and underarm swelling or tenderness. Moderna plans to collaborate with Canadian health authorities on the future availability of these vaccines in the country.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
